Most sexual health medications work on blood flow. PT-141 works differently, acting on the brain’s own desire pathway rather than the vascular system.
At Denver Wellness & Aesthetics Center (DWAC), PT-141 therapy is offered under physician oversight as part of a complete sexual wellness evaluation, led by Dr. Michael Young.
PT-141, also known as bremelanotide, is a melanocortin receptor agonist that acts on the central nervous system to influence sexual desire. Unlike medications that improve blood flow, PT-141 works on the neurological signaling behind desire itself, which is part of why it’s considered for patients whose primary concern is low desire rather than a purely physical response issue.
Bremelanotide is FDA approved, under the brand name Vyleesi, specifically for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Use in men, and use outside that specific approved population, is considered off-label.
Off-label prescribing is a legal, common, and well-established practice in medicine, and it’s why a real evaluation with a licensed physician matters here. Your provider will discuss what’s approved, what’s off-label, and what the evidence actually supports for your specific situation before recommending a course of treatment.
Low sexual desire, in women and, on an off-label basis, in men.
Situations where blood-flow-focused treatments haven’t fully addressed the concern.
Sexual wellness concerns tied to desire and motivation rather than purely physical response.
At DWAC, PT-141 is one part of a larger sexual wellness program that may also include bioidentical hormone replacement and other evidence-based therapies.
It’s also connected to our broader peptide therapy offerings, since PT-141 is a peptide-based treatment. Your provider will help determine whether PT-141, another approach, or a combination fits your specific situation.
A thorough discussion of your symptoms, health history, and goals, including a clear conversation about approved versus off-label use for your specific situation.
Your dosing and administration schedule are set based on your evaluation, not a fixed protocol applied to every patient.
Regular check-ins to assess your response and adjust your plan as needed.
Yes, for one specific use: acquired, generalized hypoactive sexual desire disorder in premenopausal women, under the brand name Vyleesi. Use in men and other populations is off-label.
Off-label prescribing is a legal, common, and accepted medical practice. Safety depends on proper evaluation and physician oversight, which is why PT-141 at DWAC always starts with a real consultation.
Those medications work by improving blood flow. PT-141 works on the brain’s desire pathway instead, which is why it’s considered for concerns centered on low desire rather than a purely physical response.
PT-141 is administered by injection, according to a schedule and dose determined by your provider based on your evaluation.
Nausea is the most commonly reported side effect in clinical use, particularly with early doses. Your provider will discuss what to expect and how it’s typically managed.
The FDA-approved indication is specific to premenopausal women with acquired, generalized HSDD. Use outside that population would be an off-label decision made between you and your provider based on your specific situation.
Low desire can stem from multiple causes, including hormonal factors. Your evaluation may consider whether hormone optimization, PT-141, or a combination best addresses what’s actually happening for you.
Adults experiencing low sexual desire, particularly where blood-flow-focused treatments haven’t fully addressed the concern, are commonly good candidates for evaluation, though a full consultation determines fit for your specific case.
Every protocol starts with a confidential evaluation by our physician-led team. Call (303) 347-2000 or request a consultation below.
(303) 347-2000 · 500 E Hampden Ave, Suite 206 · Englewood, CO 80113
